Application | Comment | Organism |
---|---|---|
medicine | biomarker used in the diagnosis of prostate cancer and to monitor therapeutic response. Design and development of potent and specific inhibitors of PSA | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
((2R,3R)-3-benzyl-1-(ethylsulfonyl)-4-oxoazetidin-2-yl)methyl benzoate | - |
Homo sapiens | |
((2R,3R)-3-benzyl-4-oxo-1-(phenylsulfonyl)azetidin-2-yl)methyl benzoate | - |
Homo sapiens | |
((2R,3R)-3-benzyl-4-oxo-1-tosylazetidin-2-yl)methyl benzoate | - |
Homo sapiens | |
((2S,3S)-3-benzyl-1-(ethylsulfonyl)-4-oxoazetidin-2-yl)methyl benzoate | - |
Homo sapiens | |
((2S,3S)-3-benzyl-4-oxo-1-(phenylsulfonyl)azetidin-2-yl)methyl benzoate | - |
Homo sapiens | |
((2S,3S)-3-benzyl-4-oxo-1-tosylazetidin-2-yl)methyl benzoate | - |
Homo sapiens | |
(2R,3R)-benzyl 1-(2-(3-(benzyloxycarbonyl)phenyl)acetyl)-3-(4-hydroxybenzyl)-4-oxoazetidine-2-carboxylate | - |
Homo sapiens | |
(2R,3R)-benzyl 1-benzoyl-3-(4-hydroxybenzyl)-4-oxoazetidine-2-carboxylate | - |
Homo sapiens | |
(2R,3R)-benzyl 3-benzyl-1-(2-(3-(benzyloxycarbonyl)phenyl)acetyl)-4-oxoazetidine-2-carboxylate | - |
Homo sapiens | |
(2R,3R)-ethyl 3-benzyl-4-oxo-1-tosylazetidine-2-carboxylate | - |
Homo sapiens | |
(2S,3S)-benzyl 1-(2-(3-(benzyloxycarbonyl)phenyl)acetyl)-3-(4-hydroxybenzyl)-4-oxoazetidine-2-carboxylate | - |
Homo sapiens | |
(2S,3S)-benzyl 1-benzoyl-3-(4-hydroxybenzyl)-4-oxoazetidine-2-carboxylate | - |
Homo sapiens | |
(2S,3S)-benzyl 3-benzyl-1-(2-(3-(benzyloxycarbonyl)phenyl)acetyl)-4-oxoazetidine-2-carboxylate | - |
Homo sapiens | |
(2S,3S)-ethyl 3-benzyl-4-oxo-1-tosylazetidine-2-carboxylate | - |
Homo sapiens | |
(3-benzyl-1-(ethylsulfonyl)-4-oxoazetidin-2-yl)methyl benzoate | - |
Homo sapiens | |
(3-benzyl-4-oxo-1-tosylazetidin-2-yl)methyl benzoate | - |
Homo sapiens | |
3-(2-((2R,3R)-3-benzyl-2-((4-carboxybenzyloxy)carbonyl)-4-oxoazetidin-1-yl)-2-oxoethyl)benzoic acid | - |
Homo sapiens | |
3-(2-((2S,3S)-3-benzyl-2-((4-carboxybenzyloxy)carbonyl)-4-oxoazetidin-1-yl)-2-oxoethyl)benzoic acid | - |
Homo sapiens | |
3-(2-(3-benzyl-2-((4-carboxybenzyloxy)carbonyl)-4-oxoazetidin-1-yl)-2-oxoethyl)benzoic acid | - |
Homo sapiens | |
4-(((2R,3R)-1-(2-(3-(benzyloxycarbonyl)phenyl)acetyl)-3-(4-hydroxybenzyl)-4-oxoazetidine-2-carbonyloxy)methyl)benzoic acid | - |
Homo sapiens | |
4-(((2R,3R)-3-benzyl-1-(2-(3-((4-carboxybenzyloxy)carbonyl)phenyl)acetyl)-4-oxoazetidine-2-carbonyloxy)methyl)benzoic acid | - |
Homo sapiens | |
4-(((2R,3R)-3-benzyl-1-(2-(3-(benzyloxycarbonyl)phenyl)acetyl)-4-oxoazetidine-2-carbonyloxy)methyl)benzoic acid | - |
Homo sapiens | |
4-(((2S,3S)-1-(2-(3-(benzyloxycarbonyl)phenyl)acetyl)-3-(4-hydroxybenzyl)-4-oxoazetidine-2-carbonyloxy)methyl)benzoic acid | - |
Homo sapiens | |
4-(((2S,3S)-3-benzyl-1-(2-(3-((4-carboxybenzyloxy)carbonyl)phenyl)acetyl)-4-oxoazetidine-2-carbonyloxy)methyl)benzoic acid | - |
Homo sapiens | |
4-(((2S,3S)-3-benzyl-1-(2-(3-(benzyloxycarbonyl)phenyl)acetyl)-4-oxoazetidine-2-carbonyloxy)methyl)benzoic acid | - |
Homo sapiens | |
4-((1-(2-(3-(benzyloxycarbonyl)phenyl)acetyl)-3-(4-hydroxybenzyl)-4-oxoazetidine-2-carbonyloxy)methyl)benzoic acid | - |
Homo sapiens | |
4-((3-benzyl-1-(2-(3-((4-carboxybenzyloxy)carbonyl)phenyl)acetyl)-4-oxoazetidine-2-carbonyloxy)methyl)benzoic acid | - |
Homo sapiens | |
4-((3-benzyl-1-(2-(3-(benzyloxycarbonyl)phenyl)acetyl)-4-oxoazetidine-2-carbonyloxy)methyl)benzoic acid | - |
Homo sapiens | |
benzyl 1-(2-(3-(benzyloxycarbonyl)phenyl)acetyl)-3-(4-hydroxybenzyl)-4-oxoazetidine-2-carboxylate | - |
Homo sapiens | |
benzyl 1-benzoyl-3-(4-hydroxybenzyl)-4-oxoazetidine-2-carboxylate | - |
Homo sapiens | |
benzyl 3-benzyl-1-(2-(3-(benzyloxycarbonyl)phenyl)acetyl)-4-oxoazetidine-2-carboxylate | - |
Homo sapiens | |
benzyl 3-benzyl-4-oxo-1-(phenylsulfonyl)azetidine-2-carboxylate | - |
Homo sapiens | |
additional information | beta-lactams inhibit PSA in a time-dependent fashion, beta-lactams bind covalently with PSA. Specificity of a lactam inhibitor toward PSA can be strengthened by optimizing its C-3 side chain to maximize the hydrophobic and the polar interactions in the S-1 pocket | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
HSSKLQ-7-amido-4-trifluoromethyl-coumarin + H2O | - |
Homo sapiens | ? | - |
? |
Synonyms | Comment | Organism |
---|---|---|
prostate specific antigen | - |
Homo sapiens |
PSA | - |
Homo sapiens |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
0.00034 | - |
- |
Homo sapiens | benzyl 1-(2-(3-(benzyloxycarbonyl)phenyl)acetyl)-3-(4-hydroxybenzyl)-4-oxoazetidine-2-carboxylate | |
0.0011 | - |
- |
Homo sapiens | (2S,3S)-ethyl 3-benzyl-4-oxo-1-tosylazetidine-2-carboxylate | |
0.00143 | - |
- |
Homo sapiens | benzyl 3-benzyl-1-(2-(3-(benzyloxycarbonyl)phenyl)acetyl)-4-oxoazetidine-2-carboxylate | |
0.0022 | - |
- |
Homo sapiens | (3-benzyl-1-(ethylsulfonyl)-4-oxoazetidin-2-yl)methyl benzoate | |
0.00308 | - |
- |
Homo sapiens | benzyl 3-benzyl-4-oxo-1-(phenylsulfonyl)azetidine-2-carboxylate | |
0.0035 | - |
- |
Homo sapiens | 4-((1-(2-(3-(benzyloxycarbonyl)phenyl)acetyl)-3-(4-hydroxybenzyl)-4-oxoazetidine-2-carbonyloxy)methyl)benzoic acid | |
0.0058 | - |
- |
Homo sapiens | 4-((3-benzyl-1-(2-(3-((4-carboxybenzyloxy)carbonyl)phenyl)acetyl)-4-oxoazetidine-2-carbonyloxy)methyl)benzoic acid | |
0.009 | - |
- |
Homo sapiens | 4-((3-benzyl-1-(2-(3-(benzyloxycarbonyl)phenyl)acetyl)-4-oxoazetidine-2-carbonyloxy)methyl)benzoic acid | |
0.01 | - |
- |
Homo sapiens | benzyl 1-benzoyl-3-(4-hydroxybenzyl)-4-oxoazetidine-2-carboxylate | |
0.1 | - |
- |
Homo sapiens | (2R,3R)-ethyl 3-benzyl-4-oxo-1-tosylazetidine-2-carboxylate |